165 related articles for article (PubMed ID: 15151939)
1. CD40 activation: potential for specific immunotherapy in B-CLL.
von Bergwelt-Baildon M; Maecker B; Schultze J; Gribben JG
Ann Oncol; 2004 Jun; 15(6):853-7. PubMed ID: 15151939
[TBL] [Abstract][Full Text] [Related]
2. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
[TBL] [Abstract][Full Text] [Related]
3. HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia.
Tolba KA; Bowers WJ; Eling DJ; Casey AE; Kipps TJ; Federoff HJ; Rosenblatt JD
Mol Ther; 2002 Oct; 6(4):455-63. PubMed ID: 12377186
[TBL] [Abstract][Full Text] [Related]
4. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells.
Pascutti MF; Jak M; Tromp JM; Derks IA; Remmerswaal EB; Thijssen R; van Attekum MH; van Bochove GG; Luijks DM; Pals ST; van Lier RA; Kater AP; van Oers MH; Eldering E
Blood; 2013 Oct; 122(17):3010-9. PubMed ID: 24014238
[TBL] [Abstract][Full Text] [Related]
5. B-cell chronic lymphocytic leukemia-derived dendritic cells stimulate allogeneic T-cell response and express chemokines involved in T-cell migration.
Łuczyński W; Stasiak-Barmuta A; Piszcz J; Iłendo E; Kowalczuk O; Krawczuk-Rybak M
Neoplasma; 2007; 54(6):527-35. PubMed ID: 17949237
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches.
Hayden RE; Pratt G; Roberts C; Drayson MT; Bunce CM
Leuk Lymphoma; 2012 Apr; 53(4):537-49. PubMed ID: 21812539
[TBL] [Abstract][Full Text] [Related]
7. T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy.
Krackhardt AM; Harig S; Witzens M; Broderick R; Barrett P; Gribben JG
Blood; 2002 Jul; 100(1):167-73. PubMed ID: 12070023
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of the CD95 receptor and defect CD40-mediated signal transduction in B-chronic lymphocytic leukemia cells.
Laytragoon-Lewin N; Duhony E; Bai XF; Mellstedt H
Eur J Haematol; 1998 Oct; 61(4):266-71. PubMed ID: 9820634
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of T cell/B cell interaction by B-CLL cells.
Kneitz C; Goller M; Wilhelm M; Mehringer C; Wohlleben G; Schimpl A; Tony HP
Leukemia; 1999 Jan; 13(1):98-104. PubMed ID: 10049067
[TBL] [Abstract][Full Text] [Related]
10. CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motility.
Girbl T; Hinterseer E; Grössinger EM; Asslaber D; Oberascher K; Weiss L; Hauser-Kronberger C; Neureiter D; Kerschbaum H; Naor D; Alon R; Greil R; Hartmann TN
Cancer Res; 2013 Jan; 73(2):561-70. PubMed ID: 23117883
[TBL] [Abstract][Full Text] [Related]
11. Vaccine- and immune-based therapy in chronic lymphocytic leukemia.
Le Dieu R; Gribben J
Semin Oncol; 2006 Apr; 33(2):220-9. PubMed ID: 16616069
[TBL] [Abstract][Full Text] [Related]
12. CD40 ligand in CLL pathogenesis and therapy.
Schattner EJ
Leuk Lymphoma; 2000 May; 37(5-6):461-72. PubMed ID: 11042507
[TBL] [Abstract][Full Text] [Related]
13. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.
Gitelson E; Hammond C; Mena J; Lorenzo M; Buckstein R; Berinstein NL; Imrie K; Spaner DE
Clin Cancer Res; 2003 May; 9(5):1656-65. PubMed ID: 12738718
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanism and function of CD40/CD40L engagement in the immune system.
Elgueta R; Benson MJ; de Vries VC; Wasiuk A; Guo Y; Noelle RJ
Immunol Rev; 2009 May; 229(1):152-72. PubMed ID: 19426221
[TBL] [Abstract][Full Text] [Related]
15. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.
Furman RR; Asgary Z; Mascarenhas JO; Liou HC; Schattner EJ
J Immunol; 2000 Feb; 164(4):2200-6. PubMed ID: 10657675
[TBL] [Abstract][Full Text] [Related]
16. Functions of CD40 and Its Ligand, gp39 (CD40L).
Laman JD; Claassen E; Noelle RJ
Crit Rev Immunol; 2017; 37(2-6):371-420. PubMed ID: 29773027
[TBL] [Abstract][Full Text] [Related]
17. Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells.
Mayr C; Kofler DM; Büning H; Bund D; Hallek M; Wendtner CM
Blood; 2005 Nov; 106(9):3223-6. PubMed ID: 16014560
[TBL] [Abstract][Full Text] [Related]
18. CD40 ligand, Bcl-2 and apoptosis in B-chronic lymphocytic leukemia.
Hussein OA; Omran AA; Elnaggar AM; Fathy A
Egypt J Immunol; 2009; 16(2):27-36. PubMed ID: 22059351
[TBL] [Abstract][Full Text] [Related]
19. Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation.
Ringelstein-Harlev S; Avivi I; Fanadka M; Horowitz NA; Katz T
Cancer Immunol Immunother; 2018 May; 67(5):739-748. PubMed ID: 29450641
[TBL] [Abstract][Full Text] [Related]
20. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
Takahashi S; Rousseau RF; Yotnda P; Mei Z; Dotti G; Rill D; Hurwitz R; Marini F; Andreeff M; Brenner MK
Hum Gene Ther; 2001 Apr; 12(6):659-70. PubMed ID: 11426465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
